175 related articles for article (PubMed ID: 38148658)
41. Hepatitis B virus X protein accelerates hepatocarcinogenesis with partner survivin through modulating miR-520b and HBXIP.
Zhang W; Lu Z; Kong G; Gao Y; Wang T; Wang Q; Cai N; Wang H; Liu F; Ye L; Zhang X
Mol Cancer; 2014 May; 13():128. PubMed ID: 24886421
[TBL] [Abstract][Full Text] [Related]
42. Value of 5-Hydroxymethylcytosine in HBV-Carrying High-Risk Hepatocellular Carcinoma Population: An Evaluation Based on Differential Analysis.
Yu J; Gao G; Wang J; Zhao J; Zhang Y; Jiang D; Huang F
Comput Math Methods Med; 2022; 2022():4835417. PubMed ID: 35651922
[TBL] [Abstract][Full Text] [Related]
43. Differential expression of hDAB2IPA and hDAB2IPB in normal tissues and promoter methylation of hDAB2IPA in hepatocellular carcinoma.
Qiu GH; Xie H; Wheelhouse N; Harrison D; Chen GG; Salto-Tellez M; Lai P; Ross JA; Hooi SC
J Hepatol; 2007 Apr; 46(4):655-63. PubMed ID: 17258345
[TBL] [Abstract][Full Text] [Related]
44. Promoter hypermethylation of DNA damage response genes in hepatocellular carcinoma.
Li Z; Zhang H; Yang J; Hao T; Li S
Cell Biol Int; 2012 May; 36(5):427-32. PubMed ID: 21864295
[TBL] [Abstract][Full Text] [Related]
45. The chemokine receptor CCR10 promotes inflammation-driven hepatocarcinogenesis via PI3K/Akt pathway activation.
Wu Q; Chen JX; Chen Y; Cai LL; Wang XZ; Guo WH; Zheng JF
Cell Death Dis; 2018 Feb; 9(2):232. PubMed ID: 29445190
[TBL] [Abstract][Full Text] [Related]
46. EYA2 suppresses the progression of hepatocellular carcinoma via SOCS3-mediated blockade of JAK/STAT signaling.
Liu ZK; Li C; Zhang RY; Wei D; Shang YK; Yong YL; Kong LM; Zheng NS; Liu K; Lu M; Liu M; Hu CX; Yang XZ; Chen ZN; Bian H
Mol Cancer; 2021 May; 20(1):79. PubMed ID: 34044846
[TBL] [Abstract][Full Text] [Related]
47. Genome-wide promoter DNA methylation profiling of hepatocellular carcinomas arising either spontaneously or due to chronic exposure to Ginkgo biloba extract (GBE) in B6C3F1/N mice.
Kovi RC; Bhusari S; Mav D; Shah RR; Ton TV; Hoenerhoff MJ; Sills RC; Pandiri AR
Arch Toxicol; 2019 Aug; 93(8):2219-2235. PubMed ID: 31278416
[TBL] [Abstract][Full Text] [Related]
48. [Expression and methylation status of Foxp3 in human hepatocellular carcinoma].
Dang S; Chen P; Zhang B; Zhou J; Shi L
Zhonghua Gan Zang Bing Za Zhi; 2014 Aug; 22(8):616-9. PubMed ID: 25243964
[TBL] [Abstract][Full Text] [Related]
49. Clinical significance of aberrant cyclin-dependent kinase-like 2 methylation in hepatocellular carcinoma.
Zhou Y; Qiu XP; Li ZH; Zhang S; Rong Y; Yang GH; Fang-Zheng
Gene; 2019 Jan; 683():35-40. PubMed ID: 30292871
[TBL] [Abstract][Full Text] [Related]
50. Methylation of S100A8 is a promising diagnosis and prognostic marker in hepatocellular carcinoma.
Liu K; Zhang Y; Zhang C; Zhang Q; Li J; Xiao F; Li Y; Zhang R; Dou D; Liang J; Qin J; Lin Z; Zhao D; Jiang M; Liang Z; Su J; Gupta VP; He M; Yang X
Oncotarget; 2016 Aug; 7(35):56798-56810. PubMed ID: 27462864
[TBL] [Abstract][Full Text] [Related]
51. Promoter hypermethylation of p14 (ARF) , RB, and INK4 gene family in hepatocellular carcinoma with hepatitis B virus infection.
Zhang JC; Gao B; Yu ZT; Liu XB; Lu J; Xie F; Luo HJ; Li HP
Tumour Biol; 2014 Mar; 35(3):2795-802. PubMed ID: 24254306
[TBL] [Abstract][Full Text] [Related]
52. Tet methylcytosine dioxygenase 2 inhibits atherosclerosis via upregulation of autophagy in ApoE-/- mice.
Peng J; Yang Q; Li AF; Li RQ; Wang Z; Liu LS; Ren Z; Zheng XL; Tang XQ; Li GH; Tang ZH; Jiang ZS; Wei DH
Oncotarget; 2016 Nov; 7(47):76423-76436. PubMed ID: 27821816
[TBL] [Abstract][Full Text] [Related]
53. Identification of genes and pathways, including the CXCL2 axis, altered by DNA methylation in hepatocellular carcinoma.
Subat S; Mogushi K; Yasen M; Kohda T; Ishikawa Y; Tanaka H
J Cancer Res Clin Oncol; 2019 Mar; 145(3):675-684. PubMed ID: 30564899
[TBL] [Abstract][Full Text] [Related]
54. Identification of intragenic methylation in the TUSC1 gene as a novel prognostic marker of hepatocellular carcinoma.
Shimizu D; Kanda M; Nomoto S; Oya H; Takami H; Hibino S; Suenaga M; Inokawa Y; Hishida M; Takano N; Nishikawa Y; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Oncol Rep; 2014 Mar; 31(3):1305-13. PubMed ID: 24366000
[TBL] [Abstract][Full Text] [Related]
55. Epigenomic profiling of DNA methylation for hepatocellular carcinoma diagnosis and prognosis prediction.
Zhang C; Ge S; Wang J; Jing X; Li H; Mei S; Zhang J; Liang K; Xu H; Zhang X; Zhang C
J Gastroenterol Hepatol; 2019 Oct; 34(10):1869-1877. PubMed ID: 31038805
[TBL] [Abstract][Full Text] [Related]
56. SIP1 is downregulated in hepatocellular carcinoma by promoter hypermethylation.
Acun T; Oztas E; Yagci T; Yakicier MC
BMC Cancer; 2011 Jun; 11():223. PubMed ID: 21645397
[TBL] [Abstract][Full Text] [Related]
57. Hypermethylation of GNA14 and its tumor-suppressive role in hepatitis B virus-related hepatocellular carcinoma.
Song G; Zhu X; Xuan Z; Zhao L; Dong H; Chen J; Li Z; Song W; Jin C; Zhou M; Xie H; Zheng S; Song P
Theranostics; 2021; 11(5):2318-2333. PubMed ID: 33500727
[TBL] [Abstract][Full Text] [Related]
58. miR-93-5p knockdown repressed hepatocellular carcinoma progression via increasing ERBB4 and TETs-dependent DNA demethylation.
Li Y; Wu B; Sun R; Zhao M; Li N
Autoimmunity; 2021 Dec; 54(8):547-560. PubMed ID: 34435526
[TBL] [Abstract][Full Text] [Related]
59. Association of low p16INK4a and p15INK4b mRNAs expression with their CpG islands methylation with human hepatocellular carcinogenesis.
Qin Y; Liu JY; Li B; Sun ZL; Sun ZF
World J Gastroenterol; 2004 May; 10(9):1276-80. PubMed ID: 15112341
[TBL] [Abstract][Full Text] [Related]
60. A prominent and conserved role for YY1 in Xist transcriptional activation.
Makhlouf M; Ouimette JF; Oldfield A; Navarro P; Neuillet D; Rougeulle C
Nat Commun; 2014 Sep; 5():4878. PubMed ID: 25209548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
